vildagliptin/metformin / Generic mfg. - LARVOL DELTA

Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes. (PubMed, Cureus) - "In contrast, dapagliflozin may be more suitable for obese patients with low HDL-C. Thus, adding either drug to metformin not only improves glycemic control (FPG and HbA1c) but also favorably influences lipid profiles, potentially reducing ASCVD risk in this population."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • APOB

Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (clinicaltrials.gov) - P4 | N=196 | Completed | Sponsor: Al-Azhar University

New P4 trial • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Identification, Isolation and Structural Elucidation of New Inner Salt Impurity in Vildagliptin and Metformin Tablet by Using Supercritical Fluid Chromatography, NMR, HRMS. (PubMed, J Sep Sci) - "The aim of the work is to identify a new impurity which was detected in vildagliptin and metformin tablets under stability storage conditions by using high-performance liquid chromatography (HPLC). The new impurity was isolated and characterized by using comprehensive analysis of HPLC, flash chromatography, supercritical fluid chromatography, Fourier transform infrared spectroscopy, high-resolution mass spectrometry, 1D-NMR [1H and 13C], and 2D-NMR (1H-1H correlated spectroscopy, total correlated spectroscopy, 1H-13C heteronuclear single quantum coherence spectroscopy, 1H-13C and 1H-15N heteronuclear multiple bond coherence spectroscopy) spectroscopic data."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study of Serum Adiponectin Levels in Type 2 Diabetes Mellitus Patients and Its Correlation with Clinical Parameters (ADA 2025) - "This study examines adiponectin levels among T2DM patients, focusing on variations across treatment regimens. This cross-sectional study included adults aged 40-70 years which are divided into three groups: newly diagnosed T2DM patients not on oral antidiabetic drugs (group 1), patients on glimepiride and metformin (group 2), and those on vildagliptin and metformin (group 3)... The combination of vildagliptin (100mg/day) and metformin (1000mg/day) significantly increased adiponectin levels, suggesting its potential anti-atherogenic effect by elevating HDL-C and reducing the coronary risk index. This study suggests DPP-4 inhibitors may help improve adiponectin levels, but larger studies are needed to confirm these findings and guide clinical recommendations"

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bullous pemphigoid associated with vildagliptin in an elderly adult with diabetes mellitus. First case in Peru. (PubMed, Rev Peru Med Exp Salud Publica) - "We report the case of a 76-year-old male patient with hypertension and DM2 who started treatment with vildagliptin and metformin. Treatment includes discontinuation of the drug and the use of corticosteroids. Vildagliptin, although safe and effective, can cause BP, which requires timely diagnosis and treatment due to its high mortality."

Journal • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Hypertension • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Vildagliptin Sustained-Release and Metformin Sustained-Release Fixed-Dose Combination in Indian Patients With Type 2 Diabetes Mellitus: A Real-World Perspective. (PubMed, Cureus) - "No serious adverse events were reported during the study. Conclusion The FDC of vildagliptin SR and metformin SR was effective, safe, and well-tolerated for managing T2DM in patients who were either newly diagnosed or inadequately controlled on other antidiabetic agents in Indian real-world settings."

Journal • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Two Rare Monogenic Diabetes Cases Due to CEL Mutations: One with MODY 8 Phenotype, One presenting as Type 1 Diabetes (ESPE-ESE 2025) - "He was on insulin glargine (28 U,OD), insulin aspart (14 U,TID), vildagliptin/metformin (BID),and dapagliflozin(OD)...Her BMI was 22 kg/m², and her physical examination was normal.She was on insulin aspart/degludec(30 U,BID) and insulin aspart(8 U,OD). HbA1c was 9.4%, C-peptide<0.1 ng/mL, and Anti-GAD was elevated(47.5 U/mL), while other diabetes-related autoantibodies were negative.Renal and liver function tests were normal, and the albumin-to-creatinine ratio was 76 mg/day, leading to ramipril(2.5 mg,OD) initiation...Conclusion Cases of diabetes associated with CEL gene mutations are extremely rare and typically present as a form of diabetes requiring insulin therapy.While these mutations can lead to monogenic diabetes cases associated with MODY-8, their potential association with T1DM, as observed in our second case, suggests a broader clinical spectrum. Increased reporting of monogenic diabetes forms will enhance the recognition of diabetes- associated genes..."

Clinical • Diabetes • Diabetic Retinopathy • Immunology • Metabolic Disorders • Renal Disease • Retinal Disorders • Type 1 Diabetes Mellitus

Comparative Bioequivalence Study of 2 Fixed-Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers. (PubMed, Clin Pharmacol Drug Dev) - "Safety assessments revealed no serious adverse events, and both products were well tolerated. The study concluded that the test product is bioequivalent to the reference, supporting its therapeutic interchangeability in managing type 2 diabetes mellitus."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GLUCOSE MANAGEMENT AFTER GASTRECTOMY: INSIGHTS FROM CONTINUOUS GLUCOSE MONITORING (ATTD 2025) - "Case 2: a 73 -year-old female with a history of total gastrectomy for gastric cancer 6 years ago and type 2 diabetes for 20 years, treated with vildagliptin, metformin, empagliflozin and gliclazide 30mg OD was evaluated for recurrent hypoglycemia. In case 2, prolonged postprandial glycemic excursions were accompanied by nocturnal hypoglycemia (Figure 3), elevated CV and increased Time Above Range (TAR) (Figure 4). In case 3, CGM was remarkable for postprandial hyperglycemia, late postprandial and nocturnal hypoglycemia (Figure 5) and increased CV, TBR and TAR (Figure 6).Conclusions CGM can effectively detect hypoglycemia and glucose fluctuations following gastrectomy in patients with and without diabetes."

Gastric Cancer • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Oncology • Solid Tumor • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Drug-induced hearing disorders: a disproportionality analysis of the FAERS database. (PubMed, Front Pharmacol) - "The top five drugs with the highest number of reported adverse events to hearing impairment were sacubitril/valsartan (2,674), adalimumab (2,479), etanercept (1,834), tofacitinib (1,812), and apixaban (1,600). The top five drugs for new signal strength are pancuronium (n = 13, ROR 67.57, PRR 53.61, IC5.74, EBGM 53.06), paromomycin (n = 6, ROR 46.3, PRR 39.33, IC5.30, EBGM 39.33), tafamidis (n = 300, ROR 14.90, PRR 14.13, IC3.82, EBGM 14.07), vildagliptin/metformin (n = 83, ROR 11.47, PRR 11.02, IC3.46, EBGM 11.01), and atorvastatin calcium/ezetimibe (n = 6, ROR 10.76, PRR 10.36, IC3.37, EBGM 10.36). Our study covered 20 years of real-world data on reports of adverse events related to hearing impairment in the FAERS database, validating previous reports and studies, as well as identifying drugs that signal new adverse events of hearing impairment, especially some drugs commonly used for the treatment of chronic diseases (a combination of hypoglycemic drugs,..."

Journal • Otorhinolaryngology

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV). (PubMed, Clin Diabetes Endocrinol) - "The twice daily triple FDC of RMV was well tolerated, safe and effective in patients with Type 2 Diabetes Mellitus uncontrolled on dual drug therapy of Metformin plus SGLT2i or Metformin plus DPP4i. The treatment led to significant improvements in glycemic control and other metabolic parameters over 24 weeks, without compromising renal function or causing serious adverse events."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

The effect of vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients: a randomized controlled trial. (PubMed, BMC Pharmacol Toxicol) - "Both vildagliptin and metformin are effective in improving glycemic control in newly diagnosed T2D patients, as evidenced by reductions in FBG and HbA1c levels. Additionally, both drugs significantly reduced the HSI, body weight, and BMI, with metformin showing a more pronounced effect on weight and BMI. Both vildagliptin and metformin effectively decreased hepatic steatosis in T2D patients. Total cholesterol and LDL are important predictors of hepatic steatosis."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial. (PubMed, Metab Syndr Relat Disord) - "No adverse events, such as severe hypoglycemia, were observed in either group. We concluded that there were no significant differences in the efficacy of two combination tablets of DPP-4 inhibitors and metformin with different dosages on glycemic control in patients with T2D."

Journal • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Deciphering the role of a causative agent: a challenge in the management of bullous dermatosis (EADV 2024) - "The list of patient ’ s chronic therapy included vildagliptin/metformin, losartan/hydrochlorothiazide, and atorvastatin, with no alterations up till 8 months before the onset of the skin lesions...Patient was treated with intravenous methylprednisolone 0.5mg/kg/day in a tapering schedule and local corticosteroid ointments, exhibiting substantial improvement, without new lesions erupting. This case highlights the complexity of diagnosing bullous pemphigoid, particularly in the context of its resemblance to other dermatological conditions such as scabies and herpes zoster. The patient ’ s presentation underscores the importance of thorough evaluation and consideration of drug-induced factors in autoimmune diseases, as illustrated in this case, given the fact that almost all of the previously mentioned medications could potentially be the cause of the onset of the disease."

Atopic Dermatitis • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Dyslipidemia • Herpes Zoster • Immunology • Infectious Disease • Metabolic Disorders • Pruritus • Pulmonary Arterial Hypertension • Type 2 Diabetes Mellitus • Urticaria • Varicella Zoster

Stability-Indicating HPLC for Remogliflozin, Vildagliptin, and Metformin: Method Development, Validation, and Greenness. (PubMed, Ann Pharm Fr) - "The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications."

Journal

Diabetes remission: experience from a randomized control trial conducted in a tertiary care hospital in India. (ENDO 2024) - "Study populations have been randomized to 1:1 to receive pharmacotherapy with oral semaglutide, dapagliflozin, and metformin in one arm and vildagliptin, metformin, and titrated glimepiride in the control arm. Remission of diabetes as defined by ADA in the consensus statement (HbA1c < 6.5 % without glucose-lowering therapy for at least 3 months) is a reality. It can be achieved by pharmacotherapy targeting body weight and adiposity. The main predictors of remission were a reduction of BMI and body fat and an increased disposition Index."

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective. (PubMed, Clin Med Insights Endocrinol Diabetes) - "Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy."

Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Bio-innova Co., Ltd

New P1 trial

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: International Bio service

New P1 trial

Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "Generally, compared to placebo, sitagliptin, vildagliptin, metformin, and bromocriptine, 20 mg of teneligliptin showed better efficacy in reducing HbA1c (MD [95% CI], -0.78 [-0.86 to -0.70], -0.08 [-0.36 to 0.19], -0.04 [-0.72 to 0.60], -0.12 [-0.65 to 0.42], and -0.50 [-0.74 to -0.26], respectively) and fasting plasma glucose (FPG) (MD [95% CI], -18.02 [-20.64 to -15.13], 1.17 [-9.39 to 11.70], -8.06 [-30.95 to 14.35], -2.75 [-18.89 to 13.01], and -34.23 [-45.93 to -22.96], respectively), and 40 mg of teneligliptin also showed better efficacy in reducing HbA1c (MD [95% CI], -0.84 [-1.03 to -0.65], -0.15 [-0.49 to 0.19], -0.10 [-0.81 to 0.57], -0.18 [-0.76 to 0.39], and -0.56 [-0.88 to -0.26], respectively) and FPG (MD [95% CI], -20.40 [-26.07 to -14.57], -1.20 [-13.21 to 10.38], -10.43 [-34.16 to 12.65], -5.13 [-22.21 to 11.66], and -36.61 [-49.33 to -24.01], respectively). Twenty milligrams or 40 mg per day was the optimal dosage regimen of teneligliptin. The results..."

Journal • Retrospective data • Review • Diabetes • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Bee Products (Anzer Honey, Pollen and Propolis) in Detection and Healing of Damage Induced by Antidiabetic Drug Vildagliptin/Metformin Hydrochloride in Healthy Human Pancreatic Cells: Cytotoxic, Genotoxic and Biochemical Studies. (PubMed, Curr Med Sci) - "This study can contribute to other studies testing the healing properties of natural products against the side effects of oral antidiabetics in human cells. In particular, Anzer honey, pollen and propolis can be used as additional foods to maintain cell viability and improve heal damage and can be evaluated against side effects in other drug studies."

Journal • Diabetes • Metabolic Disorders

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus. (PubMed, Cureus) - " Both treatment regimens were effective in terms of reduced HbA1c to achieve glycemic control. Furthermore, it is well tolerated without an increase in the risk of hypoglycemia or weight gain. Hence, this therapy has favorable outcomes for T2DM management in Indian clinical settings."

Journal • Observational data • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of a combination of gliptin and metformin on serum vitamin B12, folic acid, and ferritin levels. (PubMed, Rev Assoc Med Bras (1992)) - "After 1 year, both groups taking metformin and metformin/gliptin showed low serum ferritin and vitamin B12 levels. Therefore, vitamin B12 levels in patients using these drugs should be closely monitored. Ferritin levels can be used to indicate whether glycemic control has been achieved."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Marginal Zone B Cell Lymphoma and Non-HCV Associated Type II Cryoglobulinemic Vasculitis: A Rare Presentation (EADV 2023) - "She was taking atorvastatin, methylprednisolone (MP) 15 mg, levothyroxine, perindopril arginine, indapamide, amlodipine, vildagliptin, metformin, insulin, colchicine, pregabalin, alpha lipoic acid...A rituximab-bendamustine regimen for NMZL was planned. Entecavir treatment was started for prophylaxis of hepatitis B reactivation... Type I CG consists of monoclonal IgM or IgG; Type II consists of monoclonal IgM/polyclonal IgG immune complexes; Type III consists of polyclonal IgM and IgG. In Type II and III Mixed Cryoglobulinemia (MC), the IgM fraction has RF activity. Type I CG is usually associated with monoclonal gammopathies, whereas MC is associated with infections (HCV, HBV), autoimmune diseases, B-cell lymphomas, or solid neoplasms."

Anemia • Cardiovascular • Complement-mediated Rare Disorders • Diabetes • Diabetic Neuropathy • Endocrine Disorders • Fatigue • Fibrosis • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Lupus Nephritis • Lymphoma • Marginal Zone Lymphoma • Metabolic Disorders • Monoclonal Gammopathy • Musculoskeletal Pain • Myositis • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Pain • Rheumatoid Arthritis • Scleroderma • Solid Tumor • Systemic Sclerosis • Thrombocytosis • Type 2 Diabetes Mellitus • Vasculitis

Bullous pemphigoid after COVID-19 mRNA vaccine in a diabetic maintained on vildagliptin/metformin and glimepiride: a case report (WCD 2023) - "BACKGROUND: Bullous pemphigoid (BP), the most common autoimmune blistering disease in adults, usually occurs sporadically but can be induced by medications such as penicillamine, etanercept, anti-PD-1, and DPP-4 inhibitors such as vildagliptin...Treatment with oral methylprednisolone and clobetasol propionate ointment afforded marked improvement of pruritus, and halted progression and eruption of new blisters...However, COVID-19 vaccination is encouraged to be completed especially in those with high risk of infection with SARS-CoV-2. This case outlines the importance of medication monitoring, and the benefits of a multi-disciplinary approach to patients who present with drug-related conditions"

Clinical • Atopic Dermatitis • Bullous Pemphigoid • Dermatitis • Dermatology • Dermatopathology • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Pruritus • Respiratory Diseases • Urticaria